Literature DB >> 20472323

Trypanosoma cruzi calreticulin: a novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity.

Galia Ramírez1, Carolina Valck, María C Molina, Carolina H Ribeiro, Nandy López, Gittith Sánchez, Viviana P Ferreira, Rosario Billetta, Lorena Aguilar, Ismael Maldonado, Pedro Cattán, Wilhelm Schwaeble, Arturo Ferreira.   

Abstract

In Trypanosoma cruzi, calreticulin (TcCRT) translocates from the endoplasmic reticulum (ER) to the area of flagellum emergence. We propose herein that the parasite uses this molecule to capture complement C1, in an infective apoptotic mimicry strategy. Thus, TcCRT/C1 interactions, besides inhibiting the classical pathway of complement activation as previously shown in our laboratories, will also promote infectivity. This fact correlates with significant increases in TcCRT mRNA levels during early infection stages of a VERO cell line. In vitro, the collagenous and globular C1q domains simultaneously bind TcCRT and antigen aggregated Igs, respectively. Accordingly, mouse immunizations with TcCRT induced humoral responses that, after challenge, correlated with increased parasitemia. Thus, on the parasite surface, whole Igs anti-TcCRT promote C1 deposits on trypomastigotes while, as expected, F(ab')₂ fragments decrease it. Likewise, pretreatment of the parasites with whole anti-TcCRT antibodies augmented parasitemia and mortality in mice. In contrast, pretreatment with F(ab')₂ fragments anti-TcCRT, devoid of their capacity to provide additional C1q binding sites, was protective. Most important, while pretreatment of trypomastigotes with C1q increased infectivity in the RAW murine cell line, as well as mice mortality and parasitemia, the F(ab')₂ fragments significantly interfered with the C1q-dependent infectivity. Differently from other surface molecules involved in infectivity, TcCRT uses C1 as an adaptor molecule to recognize host cells. As expected, since TcCRT is one of several cell surface parasite molecules participating in infectivity, attempts to interfere with the C1/TcCRT interactions with F(ab')₂ fragments, were moderately but significantly effective, both in vitro and in vivo.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472323     DOI: 10.1016/j.imbio.2010.04.001

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  23 in total

1.  Trypanosoma cruzi Calreticulin Topographical Variations in Parasites Infecting Murine Macrophages.

Authors:  Andrea González; Carolina Valck; Gittith Sánchez; Steffen Härtel; Jorge Mansilla; Galia Ramírez; María Soledad Fernández; José Luis Arias; Norbel Galanti; Arturo Ferreira
Journal:  Am J Trop Med Hyg       Date:  2015-03-09       Impact factor: 2.345

2.  Triatoma infestans Calreticulin: Gene Cloning and Expression of a Main Domain That Interacts with the Host Complement System.

Authors:  Katherine Weinberger; Norberto Collazo; Juan Carlos Aguillón; María Carmen Molina; Carlos Rosas; Jaime Peña; Javier Pizarro; Ismael Maldonado; Pedro E Cattan; Werner Apt; Arturo Ferreira
Journal:  Am J Trop Med Hyg       Date:  2016-11-28       Impact factor: 2.345

3.  Amblyomma americanum tick calreticulin binds C1q but does not inhibit activation of the classical complement cascade.

Authors:  Tae Kwon Kim; Adriana Mércia Guaratini Ibelli; Albert Mulenga
Journal:  Ticks Tick Borne Dis       Date:  2015-02       Impact factor: 3.744

Review 4.  Trypanosoma cruzi antioxidant enzymes as virulence factors in Chagas disease.

Authors:  Lucía Piacenza; Gonzalo Peluffo; María Noel Alvarez; Alejandra Martínez; Rafael Radi
Journal:  Antioxid Redox Signal       Date:  2012-05-21       Impact factor: 8.401

5.  The interaction of classical complement component C1 with parasite and host calreticulin mediates Trypanosoma cruzi infection of human placenta.

Authors:  Christian Castillo; Galia Ramírez; Carolina Valck; Lorena Aguilar; Ismael Maldonado; Carlos Rosas; Norbel Galanti; Ulrike Kemmerling; Arturo Ferreira
Journal:  PLoS Negl Trop Dis       Date:  2013-08-22

6.  Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo.

Authors:  Lorena Aguilar-Guzmán; Lorena Lobos-González; Carlos Rosas; Gerardo Vallejos; Cristián Falcón; Eduardo Sosoniuk; Francisca Coddou; Lisette Leyton; David Lemus; Andrew F G Quest; Arturo Ferreira
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

7.  Entamoeba histolytica and E. dispar Calreticulin: inhibition of classical complement pathway and differences in the level of expression in amoebic liver abscess.

Authors:  Cecilia Ximénez; Enrique González; Miriam E Nieves; Angélica Silva-Olivares; Mineko Shibayama; Silvia Galindo-Gómez; Jaime Escobar-Herrera; Ma Del Carmen García de León; Patricia Morán; Alicia Valadez; Liliana Rojas; Eric G Hernández; Oswaldo Partida; René Cerritos
Journal:  Biomed Res Int       Date:  2014-04-22       Impact factor: 3.411

Review 8.  The emerging role of complement lectin pathway in trypanosomatids: molecular bases in activation, genetic deficiencies, susceptibility to infection, and complement system-based therapeutics.

Authors:  Ingrid Evans-Osses; Iara de Messias-Reason; Marcel I Ramirez
Journal:  ScientificWorldJournal       Date:  2013-02-21

9.  Calreticulin contributes to C1q-dependent recruitment of microglia in the leech Hirudo medicinalis following a CNS injury.

Authors:  Francoise Le Marrec-Croq; Annelise Bocquet-Garcon; Jacopo Vizioli; Christelle Vancamp; Francesco Drago; Julien Franck; Maxence Wisztorski; Michel Salzet; Pierre-Eric Sautiere; Christophe Lefebvre
Journal:  Med Sci Monit       Date:  2014-04-19

10.  A monoallelic deletion of the TcCRT gene increases the attenuation of a cultured Trypanosoma cruzi strain, protecting against an in vivo virulent challenge.

Authors:  Fernando J Sánchez-Valdéz; Cecilia Pérez Brandán; Galia Ramírez; Alejandro D Uncos; M Paola Zago; Rubén O Cimino; Rubén M Cardozo; Jorge D Marco; Arturo Ferreira; Miguel Ángel Basombrío
Journal:  PLoS Negl Trop Dis       Date:  2014-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.